PL2259800T3 - Zastosowanie 5-(2,6-dimorfolin-4-ylopirymidyn-4-ylo)-4-trifluorometylopirydyn-2-yloaminy do leczenia niedrobnokomórkowego raka płuca wykazującego nabytą oporność wobec modulatorów receptora dla naskórkowego czynnika wzrostu (EGFR) - Google Patents

Zastosowanie 5-(2,6-dimorfolin-4-ylopirymidyn-4-ylo)-4-trifluorometylopirydyn-2-yloaminy do leczenia niedrobnokomórkowego raka płuca wykazującego nabytą oporność wobec modulatorów receptora dla naskórkowego czynnika wzrostu (EGFR)

Info

Publication number
PL2259800T3
PL2259800T3 PL09716778T PL09716778T PL2259800T3 PL 2259800 T3 PL2259800 T3 PL 2259800T3 PL 09716778 T PL09716778 T PL 09716778T PL 09716778 T PL09716778 T PL 09716778T PL 2259800 T3 PL2259800 T3 PL 2259800T3
Authority
PL
Poland
Prior art keywords
ylamine
morpholin
egfr
pyrimidin
pyridin
Prior art date
Application number
PL09716778T
Other languages
English (en)
Inventor
Carlos Garcia-Echeverria
Sauveur-Michel Maira
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2259800T3 publication Critical patent/PL2259800T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL09716778T 2008-03-05 2009-03-04 Zastosowanie 5-(2,6-dimorfolin-4-ylopirymidyn-4-ylo)-4-trifluorometylopirydyn-2-yloaminy do leczenia niedrobnokomórkowego raka płuca wykazującego nabytą oporność wobec modulatorów receptora dla naskórkowego czynnika wzrostu (EGFR) PL2259800T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08152326 2008-03-05
PCT/EP2009/052564 WO2009109605A1 (en) 2008-03-05 2009-03-04 Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
EP09716778.7A EP2259800B1 (en) 2008-03-05 2009-03-04 Use of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine for the treatment of non small cell lung carcinoma with acquired resistance to epidermal growth factor receptor (EGFR) modulators.

Publications (1)

Publication Number Publication Date
PL2259800T3 true PL2259800T3 (pl) 2014-09-30

Family

ID=39343633

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09716778T PL2259800T3 (pl) 2008-03-05 2009-03-04 Zastosowanie 5-(2,6-dimorfolin-4-ylopirymidyn-4-ylo)-4-trifluorometylopirydyn-2-yloaminy do leczenia niedrobnokomórkowego raka płuca wykazującego nabytą oporność wobec modulatorów receptora dla naskórkowego czynnika wzrostu (EGFR)

Country Status (14)

Country Link
US (2) US20110033453A1 (pl)
EP (3) EP2259800B1 (pl)
JP (2) JP2011513364A (pl)
KR (1) KR20100131446A (pl)
CN (2) CN101959533A (pl)
AU (1) AU2009221164B2 (pl)
BR (1) BRPI0908049A2 (pl)
CA (1) CA2716518A1 (pl)
ES (1) ES2471452T3 (pl)
MX (1) MX2010009743A (pl)
PL (1) PL2259800T3 (pl)
PT (1) PT2259800E (pl)
RU (2) RU2496500C2 (pl)
WO (1) WO2009109605A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2182948T3 (pl) * 2007-07-24 2013-07-31 Novartis Ag Zastosowanie imidazochinolin do leczenia chorób EGFR-zależnych albo chorób wykazujących nabytą oporność wobec środków ukierunkowanych na członków rodziny EGFR
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
MX353308B (es) 2008-05-21 2018-01-08 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
WO2012051587A1 (en) * 2010-10-14 2012-04-19 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in egfr-driven cancers
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
BR112014007310A2 (pt) 2011-09-27 2017-04-04 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
CN102397544A (zh) * 2011-11-25 2012-04-04 百泰生物药业有限公司 一种单克隆抗体用于治疗非小细胞肺癌的用途
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
WO2014028566A1 (en) * 2012-08-16 2014-02-20 Novartis Ag Combination of pi3k inhibitor and c-met inhibitor
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
JP6387360B2 (ja) 2013-03-14 2018-09-05 ノバルティス アーゲー 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
ES2784900T3 (es) 2014-12-12 2020-10-01 Massachusetts Gen Hospital Tratamiento de metástasis cerebrales del cáncer de mama
EA202190749A1 (ru) 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии
CN111529530B (zh) * 2020-04-02 2021-06-04 中山大学 一种吡啶并咪唑类STAT3抑制剂在制备延缓或逆转TKIs获得性耐药药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
CZ20014083A3 (cs) * 1999-05-14 2002-08-14 Imclone Systems Incorporated Léčivo pro indikaci růstu refrakterních nádorů
EA013811B1 (ru) * 2002-11-21 2010-08-30 Новартис Вэксинес Энд Дайэгностикс, Инк. 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
PL2182948T3 (pl) * 2007-07-24 2013-07-31 Novartis Ag Zastosowanie imidazochinolin do leczenia chorób EGFR-zależnych albo chorób wykazujących nabytą oporność wobec środków ukierunkowanych na członków rodziny EGFR

Also Published As

Publication number Publication date
EP2259800B1 (en) 2014-05-07
CA2716518A1 (en) 2009-09-11
CN101959533A (zh) 2011-01-26
WO2009109605A1 (en) 2009-09-11
KR20100131446A (ko) 2010-12-15
JP2011513364A (ja) 2011-04-28
JP2014040446A (ja) 2014-03-06
AU2009221164B2 (en) 2012-07-26
BRPI0908049A2 (pt) 2015-08-11
US20110033453A1 (en) 2011-02-10
US20140161722A1 (en) 2014-06-12
PT2259800E (pt) 2014-08-06
RU2010140435A (ru) 2012-04-10
EP2259800A1 (en) 2010-12-15
RU2496500C2 (ru) 2013-10-27
CN105343102A (zh) 2016-02-24
MX2010009743A (es) 2010-09-28
EP2591805A1 (en) 2013-05-15
AU2009221164A1 (en) 2009-09-11
EP2599499A1 (en) 2013-06-05
JP5778735B2 (ja) 2015-09-16
ES2471452T3 (es) 2014-06-26
RU2013132018A (ru) 2015-01-20

Similar Documents

Publication Publication Date Title
PT2259800E (pt) Utililização de 5-(2,6-di-morfolin-4-il-pirimidin-4-il)-4- trifluorometil-piridin-2-ilamina para o tratamento de carcinoma pulmonar de não pequenas células com resistência adquirida aos moduladores do receptor de factor de crescimento epidérmico (egfr)
PL2376537T3 (pl) Ludzkie przeciwciała przeciwko ludzkiemu czynnikowi tkankowemu
WO2009046141A3 (en) Antisense modulation of fibroblast growth factor receptor 4 expression
HUE049886T2 (hu) Tumorspecifikus neoantigéneket tartalmazó készítmények, tumorok kezelésében történõ alkalmazásra
ZA201000419B (en) Catalyst composition, its preparation and use
ZA201005090B (en) Carbon aerogels, process for their preparation and their use
AP2010005379A0 (en) Anti-TRKA antibodies and derivatives.
IL202674A0 (en) Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma
WO2008089397A3 (en) Adrb2 cancer markers
ITMI20091618A1 (it) Pezzo composito, nonche' impiego del pezzo composito
WO2009150255A3 (en) Markers for predicting response and survival in anti-egfr treated patients
PL2155824T3 (pl) Preparat pigmentowy, sposób jego wytwarzania i jego zastosowanie
IL210514A0 (en) Pyridino-pyridinone derivatives, preparation thereof, and therapeutic use thereof
IL211713A0 (en) Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine
LT2229369T (lt) 6,7-dialkoksi-chinazolino dariniai, tinkami panaudoti su vėžiu susijusių susirgimų gydymui
ZA200902311B (en) Use of epidermal growth factor for the morphofunctional restoration of peripheral nerves in diabetic neuropathy
MX303262B (es) Composicion de locion para uso personal.
IL207629A0 (en) Novel 3-aminoalkyl-1,3-dihydro-2h-indol-2-one derivatives, preparation thereof and therapeutic use thereof
IL207722A (en) Pyridopyrazinone Derivatives as Insulators, Methods of Preparation and Use for Diabetes
FR2933609B1 (fr) Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson.
PL2242491T3 (pl) Nowatorskie zastosowanie 3,3'-diinodolilometanu
ZA201005306B (en) 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use
EP2285818A4 (en) BELOXEPINE, ITS ENANTIOMERS AND ANALOGUE FOR PAIN TREATMENT
SI2376479T1 (sl) Substituirani furankarboksamidi in njihova uporaba
PL2155851T3 (pl) Zastosowanie polimerów N-winyloimidazolowych do poprawiania własności biologicznie sfermentowanych roztworów decydujących o ich wartości